Browse by Poster Presenter

Tweets by 2023 IKCS: Europe

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

A
Albrecht Olesen, Karen Marie

Department of Clinical Epidemiology, Aarhus University
26: Anticoagulant treatment and thromboembolic events prior to diagnosis of renal cell carcinoma: Impact on stage distribution
Karen Marie Albrecht Olesen
Favorite
Azawi, Nessn

Zealand University Hospital
16: Clinical Outcome of Patients with Primary Metastatic Renal Cell Carcinoma Carefully Selected for Cytoreductive Nephrectomy: A Nationwide Real-World Data
Nessn Azawi
Favorite
21: Real-world recurrence patterns in Danish renal cell carcinoma patients
Nessn Azawi
Favorite
B
Bak, Rasmine

Department of Urology, Aarhus University Hospital, Denmark
13: Active Surveillance for Small Renal Masses: Living with an potential untreated cancer
Rasmine Bak
Favorite
Bannowsky, Andreas

Imland Hospital Rendsburg
37: The metanephric adenoma - a benign variant of the Wilms' tumor: case report of an extremely rare kidney tumor
Andreas Bannowsky
Favorite
BAUDRY, Edwige

Institut de Cancérologie de Lorraine
29: Efficacity and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: a retrospective multicentric study
Edwige BAUDRY
Favorite
Beyer, Katharina

King's College London
14: Exploring the perspectives of patients with localised kidney cancer on their treatment decisions: a qualitative study
Katharina Beyer
Favorite
Brito da Silva, José

Instituto Português de Oncologia do Porto FG, E.P.E.
36: Long survivorship in metastatic kidney cancer during targeted-therapy era
José Brito da Silva
Favorite
D
Das, Prantik

UHDB NHS Foundation Trust & University of Nottingham, School of Medicine
17: Patient characteristics, treatment patterns and outcomes for patients with renal cell carcinoma (RCC) in England
Prantik Das
Favorite
E
ElBadry, Sameh

University of Sheffield
9: Characterisation of HIF-mediated genoprotection in clear cell renal cell carcinoma
Sameh ElBadry
Favorite
G
Giles, Rachel

International Kidney Cancer Coalition
6: 2022 Global Patient Survey: Reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas
Rachel Giles
Favorite
Gruenwald, Viktor

Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany
12: T-Rex Study: Real-world evidence and patient-reported outcomes of mRCC patients treated first-line with tivozanib
Viktor Gruenwald
Favorite
32: Clinical benefit of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after checkpoint inhibitor (CPI) therapy: interim results from the Phase 2 CaboPoint trial
Viktor Gruenwald
Favorite
H
Harrison, Hannah

University of Cambridge
15: Patient experience of follow-up after surgery for kidney cancer: a focus group study
Hannah Harrison
Favorite
Hjelle, Karin

Dept. of Urology, Haukeland University Hospital, Bergen, Norway
10: The use of Renal tumor biopsies (RBx) has increased at Haukeland University Hospital(HUS) during 2008-2022
Karin Hjelle
Favorite
Humphries, Kathryn

Leeds Cancer Centre
25: 4-weekly avelumab administration plus axitinib in patients with metastatic renal cell carcinoma: A single centre analysis of patient outcomes
Kathryn Humphries
Favorite
J
Jones, James

University of Cambridge
33: Investigating response to Axitinib in Kidney Cancer with Venous Tumour Thrombus: translational analysis of the NAXIVA Trial
James Jones
Favorite
Jovaisaite, Agne

Barts Cancer Centre, Queen Mary University of London
27: Immune-related adverse events after ≥12 months of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma
Agne Jovaisaite
Favorite
Junker, Theresa

Research and Innovation Unit of Radiology
Oral Abstract: Patients’ experiences on the course of treatment after partial nephrectomy or percutaneous cryoablation of small renal cell carcinoma - a cross-sectional multicenter study
Theresa Junker
Favorite
K
Kunte, Sophie Carina

Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
11: Correlation of PSMA expression on [18F]PSMA-1007 PET with morphological changes in patients with metastatic renal cell cancer undergoing tyrosine kinase and checkpoint inhibitor therapy
Sophie Carina Kunte
Favorite
L
Lewiz -Habib, Samy

UTHSCSA
8: Understand the Biology of Kidney Cancer Progression
Samy Lewiz -Habib
Favorite
M
Malik, Azhar

NHS GREATER GLASGOW AND CLYDE
19: Real World Experience (RWE) of Ipilimumab and Nivolumab compared to Pembrolizumab and Axitinib in Advanced Renal Cell Carcinoma (RCC)
Azhar Malik
Favorite
Merrick, Sophie

MRC CTU UCL
38: REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): a multi-arm phase II trial testing reduced intensity immunotherapy across different cancers
Sophie Merrick
Favorite
N
Nathan, Paul

Mount Vernon Cancer Centre
20: A UK real-world observational study of avelumab + axitinib (A+Ax) in advanced renal cell carcinoma (RCC): exploratory analysis of 24-month interim results in patients with non-clear cell histology
Paul Nathan
Favorite
R
Rainho, Larissa

Institut Gustave Roussy
34: Baseline cytokine levels according to IMDC score in patients with metastatic clear cell renal cell carcinoma treated with nivolumab in the NIVOREN GETUG-AFU 26 Translational study
Larissa Rainho
Favorite
Ritchie, Aimi

Pfizer Oncology
20: A UK real-world observational study of avelumab + axitinib (A+Ax) in advanced renal cell carcinoma (RCC): exploratory analysis of 24-month interim results in patients with non-clear cell histology
Aimi Ritchie
Favorite
S
Sanghera, Chandan

Cambridge University Hospitals NHS Foundation Trust
28: Real world experience of managing immunotherapy toxicity at a UK tertiary centre
Chandan Sanghera
Favorite
Shaheen, Ahmed

Northern Centre for cancer care
23: Role of cytoreductive nephrectomy in metastatic RCC, single institution experience
Ahmed Shaheen
Favorite
T
Teixeira, Marcus

1. Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France
7: Circulating B cells subpopulations and outcomes to Checkpoint Blockade in patients with renal cell carcinoma.
Marcus Teixeira
Favorite
Toms, Charlotte

Barts ECMC, Barts Cancer Institute, Queen Mary University London
18: Optimal Duration of Frontline Immunotherapy in Patients with Metastatic Renal Cell Carcinoma (mRCC)
Charlotte Toms
Favorite
TRIPATHI, NIKITA

Mayo Clinic , Phoenix, Arizona
31: Efficacy of immune checkpoint inhibitor (ICI) combination therapy as first-line (1L) treatment in metastatic renal cell carcinoma (mRCC).
NIKITA TRIPATHI
Favorite
V
Vano, Yann-Alexandre

Hôpital Européen Georges Pompidou, AP-HP. Centre – Université Paris Cité, Paris, France
24: Real-world outcomes of nivolumab (NIVO) + ipilimumab (IPI) in patients with previously untreated clear cell advanced renal cell carcinoma (aRCC) in France.
Yann-Alexandre Vano
Favorite
Vaz-Ferreira, Ana

Instituto Português de Oncologia do Porto Francisco Gentil EPE
35: Renal cell carcinoma and therapeutic opportunities in the paradigm shift – a case report
Ana Vaz-Ferreira
Favorite
36: Long survivorship in metastatic kidney cancer during targeted-therapy era
Ana Vaz-Ferreira
Favorite
Venugopal, Balaji

Beatson West of Scotland Cancer Centre Glasgow, UK
22: Baseline characteristics from the real-world CARINA study of patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy
Balaji Venugopal
Favorite
Verkarre, Virginie

APHP-Centre, Université de Paris-Cité, PARCC INSERM UMR970
Oral Abstract: Eosinophilic solid and cystic renal cell carcinoma : a rare new entity associated with TSC1/TSC2 genetic alteration and rare metastatic potential.
Virginie Verkarre
Favorite
W
Wang, Yishen

Barts Health NHS Trust
30: Association of ABO blood type with toxicity and response to immunotherapy in metastatic renal cell carcinoma (mRCC)
Yishen Wang
Favorite
Wintner, Lisa

Medical University of Innsbruck
14: Exploring the perspectives of patients with localised kidney cancer on their treatment decisions: a qualitative study
Lisa Wintner
Favorite